Aradigm Corporation Reports Novo Nordisk A/S To Initiate Additional Phase 3 Clinical Trials Of AERx Diabetes Management System

Aradigm Corporation (NASDAQ: ARDM) today reported that its partner, Novo Nordisk, announced the initiation of additional Phase 3 clinical trials of the AERx® insulin Diabetes Management System (iDMS). In a press release issued this morning, Novo Nordisk stated that they will reinitiate the Phase 3 clinical program and that additional details on the corresponding clinical trials would be provided during their April 28, 2006 financial announcement.

Back to news